Cardiovascular disease in patients with chronic renal impairment: Role of natriuretic peptides

Congestive Heart Failure

Volumn 14, Issue 4, 2008, Pages 38-42

  Vanderheyden, Marc ^a   Bartunek, Jozef ^a   Filippatos, Gerasimos ^b   Goethals, Marc ^a   Vlem, Bruno Van ^c   Maisel, Alan ^d  

^a CARDIOVASCULAR CENTER   (Belgium)

^b UNIVERSITY OF ATHENS   (Greece)

^c Onze Lieve Vrouwe Ziekenhuis   (Belgium)

^d UNIVERSITY OF SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIAGNOSTIC AGENT; NATRIURETIC FACTOR;

CHRONIC KIDNEY FAILURE; HEART FAILURE; HUMAN; MASS SCREENING; PATHOLOGY; PATHOPHYSIOLOGY; PROGNOSIS; REVIEW;

HEART FAILURE; HUMANS; KIDNEY FAILURE, CHRONIC; MASS SCREENING; NATRIURETIC PEPTIDES; PROGNOSIS;

EID: 55249103103     PISSN: 15275299     EISSN: 17517133     Source Type: Journal    
DOI: 10.1111/j.1751-7133.2008.08344.x     Document Type: Review

References (54)

1. Swedberg K, Cleland J, Dargie H, et al; Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J. 2005;26(11):1115-1140.
2. Nieminen MS, Böhm M, Cowie MR, et al; ESC Committee for Practice Guideline (CPG). Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J. 2005;26(4):384-416.
3. Dries DL, Exner DV, Domanski MJ, et al. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol. 2000;35(3):681-689.
4. Fonarow GC; ADHERE Scientific Advisory Committee. The Acute Decompensated Heart Failure National Registry (ADHERE): opportunities to improve care of patients hospitalized with acute decompensated heart failure. Rev Cardiovasc Med. 2003;4(suppl 7):S21-S30.
5. Nieminen MS, Brutsaert D, Dickstein K, et al; EuroHeart Survey Investigators; Heart Failure Association, European Society of Cardiology. EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. Eur Heart J. 2006;27(22):2725-2736.
6. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351(13):1296-1305.
7. Ritz E, McClellan WM. Overview: increased cardiovascular risk in patients with minor renal dysfunction: an emerging issue with far-reaching consequences. J Am Soc Nephrol. 2004;15(3):513-516.
8. Varma R, Garrick R, McClung J, et al. Chronic renal dysfunction as an independent risk factor for the development of cardiovascular disease. Cardiol Rev. 2005;13(2):98-107.
9. Sarnak MJ. Cardiovascular complications in chronic kidney disease. Am J Kidney Dis. 2003;41(suppl 5):11-17.
10. Levin A. Clinical epidemiology of cardiovascular disease in chronic kidney disease prior to dialysis. Semin Dial. 2003;16(2):101-105.
11. Muntner P, He J, Hamm L, et al. Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States. J Am Soc Nephrol. 2002;13(3):745-753.
12. Januzzi JL Jr, Camargo CA, Anwaruddin S, et al. The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol. 2005;95(8):948-954.
13. McCullough PA, Nowak RM, McCord J, et al. B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: analysis from Breathing Not Properly (BNP) Multinational Study. Circulation. 2002;106(4):416-422.
14. McCullough PA, Sandberg KR. Sorting out the evidence on natriuretic peptides. Rev Cardiovasc Med. 2003;4(suppl 4):S13-S19.
15. Focaccio A, Volpe M, Ambrosio G, et al. Angiotensin II directly stimulates release of atrial natriuretic factor in isolated rabbit hearts. Circulation. 1993;87(1):192-198.
16. Munagala VK, Burnett JC Jr, Redfield MM. The natriuretic peptides in cardiovascular medicine. Curr Probl Cardiol. 2004;29(12):707-769.
17. de Lemos JA, McGuire DK, Drazner MH. B-type natriuretic peptide in cardiovascular disease. Lancet. 2003;362(9380):316-322.
18. Valli N, Gobinet A, Bordenave L. Review of 10 years of the clinical use of brain natri-uretic peptide in cardiology. J Lab Clin Med. 1999;134(5):437-444.
19. Kishimoto I, Nakao K, Suga S, et al. Downregulation of C-receptor by natri-uretic peptides via ANP-B receptor in vascular smooth muscle cells. Am J Physiol. 1993;265(4, pt 2):H1373-H1379.
20. Lainchbury JG, Nicholls MG, Espiner EA, et al. Regional plasma levels of cardiac peptides and their response to acute neutral endo-peptidase inhibition in man. Clin Sci (Lond). 1998;95(5):547-555.
21. Pemberton CJ, Johnson ML, Yandle TG, et al. Deconvolution analysis of cardiac natri-uretic peptides during acute volume overload. Hypertension. 2000;36(3):355-359.
22. Ng LL, Geeranavar S, Jennings SC, et al. Diagnosis of heart failure using urinary natriuretic peptides. Clin Sci (Lond). 2004;106(2):129-133.
23. Kemperman H, van den Berg M, Kirkels H, et al. B-type natriuretic peptide (BNP) and N-terminal proBNP in patients with end-stage heart failure supported by a left ventricular assist device. Clin Chem. 2004;50(9):1670-1672.
24. Vanderheyden M, Bartunek J, Goethals M. Brain and other natriuretic peptides: molecular aspects. Eur J Heart Fail. 2004;6(3):261-268.
25. McCullough PA, Duc P, Omland T, et al; Breathing Not Properly Multinational Study Investigators. B-type natriuretic peptide and renal function in the diagnosis of heart failure: an analysis from the Breathing Not Properly Multinational Study. Am J Kidney Dis. 2003;41(3):571-579.
26. Totsune K, Takahashi K, Satoh F, et al. Urinary immunoreactive brain natriuretic pep-tide in patients with renal disease. Regul Pept. 1996;63(2-3):141-147.
27. Freda BJ, Francis GS. Natriuretic peptides and renal insufficiency: clinical significance and role of renal clearance. Heart Fail Clin. 2006;2(3):277-290.
28. Miller WL, Hartman KA, Burritt MF, et al. Biomarker responses during and after treatment with nesiritide infusion in patients with decompensated chronic heart failure. Clin Chem. 2005;51(3):569-577.
29. Forfia PR, Watkins SP, Rame JE, et al. Relationship between B-type natriuretic pep-tides and pulmonary capillary wedge pressure in the intensive care unit. J Am Coll Cardiol. 2005;45(10):1667-1671.
30. Tsutamoto T, Wada A, Sakai H, et al. Relationship between renal function and plasma brain natriuretic peptide in patients with heart failure. J Am Coll Cardiol. 2006;47(3):582-586.
31. McAlister FA, Ezekowitz J, Tonelli M, et al. Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study. Circulation. 2004;109(8):1004-1009.
32. Cleland JG, Swedberg K, Follath F, et al; Study Group on Diagnosis of the Working Group on Heart Failure of the European Society of Cardiology. The EuroHeart Failure survey programme-a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J. 2003;24(5):442-463.
33. Takami Y, Horio T, Iwashima Y, et al. Diagnostic and prognostic value of plasma brain natri-uretic peptide in non-dialysis-dependent CRF. Am J Kidney Dis. 2004;44(3):420-428.
34. Carr SJ, Bavanandan S, Fentum B, et al. Prognostic potential of brain natriuretic peptide (BNP) in predialysis chronic kidney disease patients. Clin Sci (Lond). 2005;109(1):75-82.
35. Spanaus KS, Kronenberg F, Ritz E, et al; Mild-to-Moderate Kidney Disease Study Group. B-type natriuretic peptide concentrations predict the progression of nondia-betic chronic kidney disease: the Mild-to-Moderate Kidney Disease Study. Clin Chem. 2007;53(7):1264-1272.
36. van Kimmenade RR, Januzzi JL Jr, Baggish AL, et al. Amino-terminal pro-brain natri-uretic Peptide, renal function, and outcomes in acute heart failure: redefining the car-diorenal interaction? J Am Coll Cardiol. 2006;48(8):1621-1627.
37. Zoccali C, Mallamaci F, Benedetto FA, et al; Creed Investigators. Cardiac natri-uretic peptides are related to left ventricular mass and function and predict mortality in dialysis patients. J Am Soc Nephrol. 2001;12(7):1508-1515.
38. Naganuma T, Sugimura K, Wada S, et al. The prognostic role of brain natriuretic pep-tides in hemodialysis patients. Am J Nephrol. 2002;22(5-6):437-444.
39. Cataliotti A, Malatino LS, Jougasaki M, et al. Circulating natriuretic peptide concentrations in patients with end-stage renal disease: role of brain natriuretic peptide as a biomarker for ventricular remodeling. Mayo Clin Proc. 2001;76(11):1111-1119.
40. Sommerer C, Beimler J, Schwenger V, et al. Cardiac biomarkers and survival in haemodialysis patients. Eur J Clin Invest. 2007;37(5):350-356.
41. Mehta RL. Continuous renal replacement therapy in the critically ill patient. Kidney Int. 2005;67(2):781-795.
42. Wahl HG, Graf S, Renz H, et al. Elimination of the cardiac natriuretic peptides B-type natriuretic peptide (BNP) and N-terminal proBNP by hemodialysis. Clin Chem. 2004;50(6):1071-1074.
43. Lee SW, Song JH, Kim GA, et al. Plasma brain natriuretic peptide concentration on assessment of hydration status in hemodialysis patient. Am J Kidney Dis. 2003;41(6):1257-1266.
44. Madsen LH, Ladefoged S, Corell P, et al. N-terminal pro brain natriuretic peptide predicts mortality in patients with end-stage renal disease in hemodialysis. Kidney Int. 2007;71(6):548-554.
45. Akiba T, Tachibana K, Togashi K, et al. Plasma human brain natriuretic peptide in chronic renal failure. Clin Nephrol. 1995;44(suppl 1):S61-S64.
46. Lang CC, Choy AM, Turner K, et al. The effect of intravenous saline loading on plasma levels of brain natriuretic peptide in man. J Hypertens. 1993;11(7):737-741.
47. Fagugli RM, Palumbo B, Ricciardi D, et al. Association between brain natriuretic peptide and extracellular water in hemo-dialysis patients. Nephron Clin Pract. 2003;95(2):c60-c66.
48. Nishikimi T, Futoo Y, Tamano K, et al. Plasma brain natriuretic peptide levels in chronic hemodialysis patients: influence of coronary artery disease. Am J Kidney Dis. 2001;37(6):1201-1208.
49. Levey AS, Beto JA, Coronado BE, et al. Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. Am J Kidney Dis. 1998;32(5):853-906.
50. Murphy SW, Foley RN, Parfrey PS. Screening and treatment for cardiovascular disease in patients with chronic renal disease. Am J Kidney Dis. 1998;32(5 suppl 3):S184-S199.
51. Ohtake T, Kobayashi S, Moriya H, et al. High prevalence of occult coronary artery stenosis in patients with chronic kidney disease at the initiation of renal replacement therapy: an angiographic examination. J Am Soc Nephrol. 2005;16(4):1141-1148.
52. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigattors. N Engl J Med. 1992;327(10):685-691.
53. Mallamaci F, Zoccali C, Tripepi G, et al; CREED Investigators, The Cardiovascular Risk Extended Evaluation. Diagnostic potential of cardiac natriuretic peptides in dialysis patients. Kidney Int. 2001;59(4):1559-1566.
54. Mark PB, Stewart GA, Gansevoort RT, et al. Diagnostic potential of circulating natriuretic peptides in chronic kidney disease. Nephrol Dial Transplant. 2006;21(2):402-410.